×
About 620 results

ALLMedicine™ Prurigo Nodularis Center

Research & Reviews  177 results

Evaluation of risk in chronic cutaneous inflammatory conditions for malignant transform...
https://doi.org/10.1111/jdv.18663
Journal of the European Academy of Dermatology and Venere... Ju T, Hernandez L et. al.

Oct 18th, 2022 - Skin carcinomas are the most common form of cancer, and every year thousands of people die from skin cancer-related malignancies. Chronic inflammation is linked to the development and progression of cancer in multiple organ systems - about 20% of ...

An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis
https://clinicaltrials.gov/ct2/show/NCT04501666

Oct 13th, 2022 - The primary objective is to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (>=) 18 years of age with prurigo nodularis (PN) after a 16 week treatment period.

A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
https://clinicaltrials.gov/ct2/show/NCT04204616

Oct 13th, 2022 - The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).

Children atopic dermatitis: Diagnosis, mimics, overlaps, and therapeutic implication.
https://doi.org/10.1111/dth.15901
Dermatologic Therapy; Napolitano M, Fabbrocini G et. al.

Oct 7th, 2022 - Atopic dermatitis (AD) is a chronic inflammatory, itching skin with a significant psychosocial impact on patients and relatives. In adults and adolescents besides flexural eczema, head and neck eczema, and hand eczema, which are the most frequent ...

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)
https://clinicaltrials.gov/ct2/show/NCT04202679

Sep 28th, 2022 - The duration of study for each participant will include 2-4 weeks of screening period, 24 weeks of treatment period and 12 weeks of post treatment period.

see more →

Clinicaltrials.gov  24 results

A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
https://clinicaltrials.gov/ct2/show/NCT04204616

Oct 13th, 2022 - The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).

An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis
https://clinicaltrials.gov/ct2/show/NCT04501666

Oct 13th, 2022 - The primary objective is to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (>=) 18 years of age with prurigo nodularis (PN) after a 16 week treatment period.

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis
https://clinicaltrials.gov/ct2/show/NCT03816891

Sep 28th, 2022 - This is a Phase 2a/b randomized, double-blind, placebo-controlled study to investigate the efficacy, safety, tolerability, PK and immunogenicity of Vixarelimab administered subcutaneously (SC) in subjects with prurigo nodularis experiencing prurit...

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)
https://clinicaltrials.gov/ct2/show/NCT04202679

Sep 28th, 2022 - The duration of study for each participant will include 2-4 weeks of screening period, 24 weeks of treatment period and 12 weeks of post treatment period.

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
https://clinicaltrials.gov/ct2/show/NCT05061693

Sep 16th, 2022 - The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension period.

see more →

News  47 results

Dupilumab Gets First FDA-Approved Indication for Prurigo Nodularis
https://www.medpagetoday.com/dermatology/generaldermatology/100967

Sep 29th, 2022 - The FDA has approved dupilumab (Dupixent) as the first treatment with an indication for prurigo nodularis, Sanofi and Regeneron announced. A chronic inflammatory skin condition affecting about 75,000 Americans, prurigo nodularis causes persistent ...

FDA Approves Dupilumab for Treatment of Prurigo Nodularis
https://www.medscape.com/viewarticle/981630

Sep 29th, 2022 - The Food and Drug Administration has approved dupilumab for treating adults with prurigo nodularis, the first treatment approved for this indication, according to a press release from the manufacturers. Recent studies of dupilumab (Dupixent), whic...

Dupilumab Offers 'Clinically Meaningful' Improvements in Prurigo Nodularis
https://www.medscape.com/viewarticle/980511

Sep 9th, 2022 - Patients with prurigo nodularis (PN) who had severe itch and high lesion counts and whose condition was inadequately controlled with prior therapies experienced significant improvements with dupilumab (Dupixent), indicate results from the phase 2 ...

Senator May Need Amputation; 1 in 5 Still Have Long COVID; Bye Bye, Juul?
https://www.medpagetoday.com/infectiousdisease/covid19/99388

Jun 23rd, 2022 - Note that some links may require registration or subscription. North Dakota Sen. Kevin Cramer (R) revealed he may need fingers on his right hand amputated after suffering an injury while doing yard work. (The Hill) Of the more than 40% of adults i...

Dupilumab Treats Itch and Clears Lesions in Prurigo Nodularis Patients
https://www.medscape.com/viewarticle/971314

Mar 31st, 2022 - BOSTON ― Dupilumab, a human monoclonal IgG4 antibody, was an effective treatment for prurigo nodularis (PN), improving itching and skin lesions after 12 and 24 weeks of treatment, in a phase 3 trial presented at the American Academy of Dermatology...

see more →